Viaderma Valuation
| VDRM Stock | USD 0.0007 0.0002 40.00% |
Viaderma seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Viaderma from inspecting the company fundamentals such as Price To Book of 0 X, return on asset of -0.91, and Shares Outstanding of 137.32 K as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Viaderma's price fluctuation is out of control at this time. Calculation of the real value of Viaderma is based on 3 months time horizon. Increasing Viaderma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Viaderma pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Viaderma. Since Viaderma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viaderma Pink Sheet. However, Viaderma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.0E-4 | Real 5.74E-4 | Hype 6.59E-4 | Naive 0.002204 |
The intrinsic value of Viaderma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Viaderma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Viaderma helps investors to forecast how Viaderma pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viaderma more accurately as focusing exclusively on Viaderma's fundamentals will not take into account other important factors: Viaderma Total Value Analysis
Viaderma is at this time projected to have valuation of 6.18 M with market capitalization of 82.27 K, debt of 0, and cash on hands of 13.08 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Viaderma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.18 M | 82.27 K | 0 | 13.08 K |
Viaderma Investor Information
The company has Price to Book (P/B) ratio of 0.0. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Viaderma had not issued any dividends in recent years. The entity had 1:50 split on the 6th of May 2014. Based on the key measurements obtained from Viaderma's financial statements, Viaderma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Viaderma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Viaderma has an asset utilization ratio of 10.48 percent. This suggests that the Company is making $0.1 for each dollar of assets. An increasing asset utilization means that Viaderma is more efficient with each dollar of assets it utilizes for everyday operations.Viaderma Profitability Analysis
The company reported the previous year's revenue of 44.69 K. Net Loss for the year was (1.52 M) with profit before overhead, payroll, taxes, and interest of 37.63 K.About Viaderma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Viaderma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Viaderma based exclusively on its fundamental and basic technical indicators. By analyzing Viaderma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Viaderma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Viaderma. We calculate exposure to Viaderma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Viaderma's related companies.ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California. Viaderma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Viaderma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Viaderma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Viaderma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Viaderma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Viaderma's revenue streams: Identify Viaderma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Viaderma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Viaderma's growth potential: Evaluate Viaderma's management, business model, and growth potential.
- Determine Viaderma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Viaderma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Viaderma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Viaderma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | -8.8 M |
Other Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.